November 26, 2013
Malvern, PA - November 26, 2013 - Egalet Corporation (“Egalet”) announced today that it has entered into a definitive collaboration and license agreement with Shionogi Limited...more
September 12, 2013
Egalet Announces Financing to Fund Abuse-Deterrent Medications
Malvern, PA – Sept. 12, 2013 – Egalet Ltd., a specialty pharmaceutical company developing and planning to commercialize abuse-deterrent oral products for the treatment of pain and other indications...more
May 8, 2013
Egalet appoints Stan Musial as CFO
Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today the appointment of Stan Musial as chief financial officer (CFO)...more
February 8, 2013
Egalet to present at BIO CEO & Investor Conference
Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today Bob Radie, president and chief executive officer (CEO), will present at the BIO CEO & Investor Conference on Tuesday, February 12 at 9:15. Mr. Radie will review the company’s patented technology and pipeline of abuse-deterrent opioids that are nearing phase 3. …more
June 03, 2012
Egalet secures $14.3 million and hires CEO Bob Radie
Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-resistant medications, announced today that it has raised $14.3 million in a Series B financing round adding CLS Capital to the existing group of investors that includes Atlas Venture, Omega Funds, Sunstone Capital and Index Ventures. In addition, the company has appointed Bob Radie as president and chief executive officer (CEO)…more
May 17, 2012
Egalet to present at Life Science Europe
Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today Bob Radie, president and chief executive officer (CEO), will present at the Life Sciences Europe conference on May 23 organized by the International Venture Club. Mr. Radie will review the company’s patented technology and pipeline of abuse-deterrent opioids that are nearing phase 3…more